State of Minnesota Report issue

Government Phase 2

Organization Overview

First Clinical Trial
2017
NCT03268603
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Minnesota Department of Employment and Economic Development | Minnesota Department of Labor and Industry | State of Minnesota Regenerative Medicine Minnesota | State of Minnesota Spinal Cord Injury and Traumatic Brain Injury Research Grant Program

Active Ingredients

Drugs in Phase 2 Trials (1)

autologous adipose-derived mesenchymal stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1